List of Field Safety Notices from 12 to 16 January 2026.
Similar Posts
MHRA approves nogapendekin alfa inbakicept to treat adult patients with non-muscle invasive bladder cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 July 2025, approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG-unresponsive non-muscle invasive bladder cancer, where the disease remains confined to the inner lining of the bladder and may include tumours.
Corporate report: Human Medicines Regulations 2012 Advisory Bodies Annual Report 2024
Annual Report of the Human Medicines Regulations 2012 Advisory Bodies – the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission.
MHRA CEO Lawrence Tallon welcomes Life Sciences Sector Plan
The Life Sciences Sector plan was released today (16 July 2025)
Medicines: Get integrated scientific advice from the MHRA and NICE
Using the Integrated Scientific Advice service from the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE).
MHRA’s 2024–25 Annual Report and Accounts and Impact Report show progress on safety, innovation, and regulatory excellence
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2024–25 Annual Report and Accounts, and accompanying Impact Report.
Class 4 Medicines Defect Notification: Flamingo Pharma UK Ltd, Amitriptyline Hydrochloride 10mg, 25mg, 50mg Tablets, EL(25)A/52
Flamingo Pharma UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information.